# Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia

## TL;DR

Daprodustat helps protect kidney function and treat anemia in patients with chronic kidney disease, especially when used early.

## Contribution

This study shows daprodustat's renoprotective effects in slowing chronic kidney disease progression.

## Key findings

- Daprodustat slowed the decline in estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease.
- Some patients showed recovery of renal function while using daprodustat.
- The renoprotective effect was limited in patients with very high serum creatinine levels.

## Abstract

Many large-scale studies revealed that exogenous erythropoietin, erythropoiesis-stimulating agents, have no renoprotective effects. We reported the renoprotective effects of endogenous erythropoietin production on renal function in ischemic reperfusion injury (IRI) of the kidney using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat. The purpose of this study was to investigate the effects of daprodustat on the progression of chronic renal failure. We retrospectively investigated the effects of daprodustat on the progression of chronic renal failure and renal anemia in patients with stages 3a-5 chronic kidney diseases (estimated glomerular filtration rate, eGFR < 60 mL/min/1.73 m2). The results show that daprodustat largely slowed the reduction in eGFR. The recovery of renal function was observed in some patients. Daprodustat is useful not only for renal anemia but also for the preservation of renal function. The renoprotective effect of daprodustat was small in patients with serum creatinine larger than 3–4 mg/dL because of low residual renal function. The appearance of renal anemia would be a sign of the time to start using daprodustat.